AU2009244199B2 - Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds - Google Patents

Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds Download PDF

Info

Publication number
AU2009244199B2
AU2009244199B2 AU2009244199A AU2009244199A AU2009244199B2 AU 2009244199 B2 AU2009244199 B2 AU 2009244199B2 AU 2009244199 A AU2009244199 A AU 2009244199A AU 2009244199 A AU2009244199 A AU 2009244199A AU 2009244199 B2 AU2009244199 B2 AU 2009244199B2
Authority
AU
Australia
Prior art keywords
alkyl
pct
pain
compound
hexahydropyrido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009244199A
Other languages
English (en)
Other versions
AU2009244199A1 (en
Inventor
Richard L. Beard
Smita Bhat
Ken Chow
John E. Donello
Michael E. Garst
Santosh C. Sinha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AU2009244199A1 publication Critical patent/AU2009244199A1/en
Application granted granted Critical
Publication of AU2009244199B2 publication Critical patent/AU2009244199B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2009244199A 2008-05-08 2009-05-07 Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds Ceased AU2009244199B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5153308P 2008-05-08 2008-05-08
US61/051,533 2008-05-08
US12/433,978 2009-05-01
US12/433,978 US20090281322A1 (en) 2008-05-08 2009-05-01 THERAPEUTICALLY USEFUL SUBSTITUTED 1,7-DIPHENYL-1,2,3,5,6,7-HEXAHYDROPYRIDO[3,2,1-Ij]QUINOLINE COMPOUNDS
PCT/US2009/043149 WO2009137681A1 (en) 2008-05-08 2009-05-07 Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds

Publications (2)

Publication Number Publication Date
AU2009244199A1 AU2009244199A1 (en) 2011-10-06
AU2009244199B2 true AU2009244199B2 (en) 2013-09-19

Family

ID=40863539

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009244199A Ceased AU2009244199B2 (en) 2008-05-08 2009-05-07 Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds

Country Status (10)

Country Link
US (1) US20090281322A1 (OSRAM)
EP (1) EP2294069B1 (OSRAM)
JP (1) JP5432246B2 (OSRAM)
CN (1) CN102089306A (OSRAM)
AU (1) AU2009244199B2 (OSRAM)
BR (1) BRPI0912534A2 (OSRAM)
CA (1) CA2723798A1 (OSRAM)
IL (1) IL209200A0 (OSRAM)
RU (1) RU2010149312A (OSRAM)
WO (1) WO2009137681A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013024657A2 (pt) * 2011-03-25 2016-12-20 Allergan Inc antagonistas da s1p como hipotensivos oculares adjuntos
KR101691954B1 (ko) 2016-04-26 2017-01-02 고려대학교 산학협력단 신규 n-아실유레아 유도체 및 이를 함유하는 심혈관질환의 예방 또는 치료용 조성물
CN107369775B (zh) * 2017-07-13 2018-12-25 长春海谱润斯科技有限公司 一种有机电致发光材料及其有机发光器件
CN107492597B (zh) * 2017-08-10 2018-11-27 长春海谱润斯科技有限公司 一种顶发射有机发光器件

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062392A2 (en) * 2002-01-18 2003-07-31 Ceretek Llc Methods of treating conditions associated with an edg receptor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003263413A1 (en) * 2002-09-17 2004-04-08 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
US20040131648A1 (en) * 2002-10-24 2004-07-08 The Procter & Gamble Company Nuclear hormone receptor compounds, products and methods employing same
US20040167185A1 (en) * 2003-01-16 2004-08-26 Geetha Shankar Methods of treating conditions associated with an Edg-3 receptor
EP2298770A1 (en) * 2005-11-03 2011-03-23 ChemBridge Corporation Heterocyclic compounds as TrkA modulators
WO2007112322A2 (en) * 2006-03-28 2007-10-04 Allergan, Inc. Indole compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062392A2 (en) * 2002-01-18 2003-07-31 Ceretek Llc Methods of treating conditions associated with an edg receptor

Also Published As

Publication number Publication date
BRPI0912534A2 (pt) 2015-10-13
JP2011527286A (ja) 2011-10-27
EP2294069A1 (en) 2011-03-16
JP5432246B2 (ja) 2014-03-05
CN102089306A (zh) 2011-06-08
IL209200A0 (en) 2011-01-31
EP2294069B1 (en) 2015-09-02
AU2009244199A1 (en) 2011-10-06
US20090281322A1 (en) 2009-11-12
WO2009137681A1 (en) 2009-11-12
CA2723798A1 (en) 2009-11-12
RU2010149312A (ru) 2012-06-20

Similar Documents

Publication Publication Date Title
EP2643299B1 (en) Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
CA3087283A1 (en) Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
MX2015005562A (es) Compuestos de piridilo sustituidos con heteroarilo utiles como moduladores de cinasa.
CA2494785A1 (en) Dihydropyrazolopyridine compounds
WO1995006648A1 (fr) Derive d'imidazoquinazoline
KR20140116379A (ko) 포밀 펩타이드 수용체 유사-1(fprl-1) 수용체 조절자로서 2,5-다이옥소이미다졸리딘-1-일-3-페닐유레아 유도체
JP2022528251A (ja) 置換複素環式アミド化合物、その調製方法、及びその医薬的使用
TW202216677A (zh) 作為ａｌｋ５抑制劑之嗒基胺基衍生物
KR102293986B1 (ko) 이소퀴놀리논 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물
TW202328102A (zh) 作為ａｌｋ５抑制劑之嗒𠯤基胺基衍生物
DK170376B1 (da) I 2-stillingen heterocyclisk substituerede 4-aryl-5-carbamoyl-6-methyl-1,4-dihydropyridin-3-carboxylsyre-forbindelser, forbindelserne til medicinsk anvendelse, anvendelse af forbindelserne til fremstilling af et lægemiddel til behandling af allergiske og inflammatoriske tilstande, farmaceutiske præparater indeholdende forbindelserne samt 2-acyl-3-aryl-propensyreestere til anvendelse som mellemprod
AU2009244199A1 (en) Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds
HUT74678A (en) Imidazo[1,2-a]pyrazine-4-one, preparation thereof and drugs containing same
US6977262B2 (en) Dihydropyrazolopyridine compounds and pharmaceutical use thereof
US8431702B2 (en) Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds
MX2015004500A (es) Derivados de 6-aminoindol como antagonistas del canal receptor de potencial transitorio (trp).
JP2006516144A (ja) インテグリン受容体アンタゴニスト誘導体としてのチアゾール化合物
JP2016504988A (ja) イミダゾピリジン誘導体
WO2025124462A1 (zh) 三环稠杂环类pde3/4双重抑制剂及其制备方法与应用
JP2025124692A (ja) 神経障害の治療に使用するための化合物
JP2015532282A (ja) β−セクレターゼの阻害剤

Legal Events

Date Code Title Description
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 08 DEC 2010 TO 08 JUN 2011 IN WHICH TO ENTER THE NATIONAL PHASE HAS BEEN FILED .

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO ENTER THE NATIONAL PHASE HAS BEEN EXTENDED TO 08 JUN 2011.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired